| DTT Name |
HUMAN janus kinase 1 (JAK-1)
|
| Synonyms |
Tyrosine-protein kinase JAK1; JAK1B; JAK1A |
| Gene Name |
JAK1
|
| BioChemical Class |
Kinase
|
| UniProt ID |
|
| TTD ID |
|
| 3D Structure |
|
| EC Number |
EC 2.7.10.2
|
| Sequence |
MQYLNIKEDCNAMAFCAKMRSSKKTEVNLEAPEPGVEVIFYLSDREPLRLGSGEYTAEEL
CIRAAQACRISPLCHNLFALYDENTKLWYAPNRTITVDDKMSLRLHYRMRFYFTNWHGTN
DNEQSVWRHSPKKQKNGYEKKKIPDATPLLDASSLEYLFAQGQYDLVKCLAPIRDPKTEQ
DGHDIENECLGMAVLAISHYAMMKKMQLPELPKDISYKRYIPETLNKSIRQRNLLTRMRI
NNVFKDFLKEFNNKTICDSSVSTHDLKVKYLATLETLTKHYGAEIFETSMLLISSENEMN
WFHSNDGGNVLYYEVMVTGNLGIQWRHKPNVVSVEKEKNKLKRKKLENKHKKDEEKNKIR
EEWNNFSYFPEITHIVIKESVVSINKQDNKKMELKLSSHEEALSFVSLVDGYFRLTADAH
HYLCTDVAPPLIVHNIQNGCHGPICTEYAINKLRQEGSEEGMYVLRWSCTDFDNILMTVT
CFEKSEQVQGAQKQFKNFQIEVQKGRYSLHGSDRSFPSLGDLMSHLKKQILRTDNISFML
KRCCQPKPREISNLLVATKKAQEWQPVYPMSQLSFDRILKKDLVQGEHLGRGTRTHIYSG
TLMDYKDDEGTSEEKKIKVILKVLDPSHRDISLAFFEAASMMRQVSHKHIVYLYGVCVRD
VENIMVEEFVEGGPLDLFMHRKSDVLTTPWKFKVAKQLASALSYLEDKDLVHGNVCTKNL
LLAREGIDSECGPFIKLSDPGIPITVLSRQECIERIPWIAPECVEDSKNLSVAADKWSFG
TTLWEICYNGEIPLKDKTLIEKERFYESRCRPVTPSCKELADLMTRCMNYDPNQRPFFRA
IMRDINKLEEQNPDIVSEKKPATEVDPTHFEKRFLKRIRDLGEGHFGKVELCRYDPEGDN
TGEQVAVKSLKPESGGNHIADLKKEIEILRNLYHENIVKYKGICTEDGGNGIKLIMEFLP
SGSLKEYLPKNKNKINLKQQLKYAVQICKGMDYLGSRQYVHRDLAARNVLVESEHQVKIG
DFGLTKAIETDKEYYTVKDDRDSPVFWYAPECLMQSKFYIASDVWSFGVTLHELLTYCDS
DSSPMALFLKMIGPTHGQMTVTRLVNTLKEGKRLPCPPNCPDEVYQLMRKCWEFQPSNRT
SFQNLIEGFEALLK
|
| Function |
Kinase partner for the interleukin (IL)-2 receptor as well as interleukin (IL)-10 receptor. Tyrosine kinase of the non-receptor type, involved in the IFN-alpha/beta/gamma signal pathway. |
| KEGG Pathway |
- EGFR tyrosine kinase inhibitor resistance (hsa01521 )
- PI3K-Akt signaling pathway (hsa04151 )
- Necroptosis (hsa04217 )
- Osteoclast differentiation (hsa04380 )
- Signaling pathways regulating pluripotency of stem cells (hsa04550 )
- NOD-like receptor signaling pathway (hsa04621 )
- JAK-STAT signaling pathway (hsa04630 )
- Th1 and Th2 cell differentiation (hsa04658 )
- Th17 cell differentiation (hsa04659 )
- Leishmaniasis (hsa05140 )
- Toxoplasmosis (hsa05145 )
- Tuberculosis (hsa05152 )
- Hepatitis C (hsa05160 )
- Hepatitis B (hsa05161 )
- Measles (hsa05162 )
- Human cytomegalovirus infection (hsa05163 )
- Influenza A (hsa05164 )
- Human papillomavirus infection (hsa05165 )
- Human T-cell leukemia virus 1 infection (hsa05166 )
- Kaposi sarcoma-associated herpesvirus infection (hsa05167 )
- Herpes simplex virus 1 infection (hsa05168 )
- Epstein-Barr virus infection (hsa05169 )
- Coronavirus disease - COVID-19 (hsa05171 )
- Pathways in cancer (hsa05200 )
- Viral carcinogenesis (hsa05203 )
- Pancreatic cancer (hsa05212 )
- PD-L1 expression and PD-1 checkpoint pathway in cancer (hsa05235 )
|
| Reactome Pathway |
- MAPK3 (ERK1) activation (R-HSA-110056 )
- MAPK1 (ERK2) activation (R-HSA-112411 )
- ISG15 antiviral mechanism (R-HSA-1169408 )
- Interleukin-7 signaling (R-HSA-1266695 )
- Other interleukin signaling (R-HSA-449836 )
- RAF/MAP kinase cascade (R-HSA-5673001 )
- Interleukin-10 signaling (R-HSA-6783783 )
- Interleukin-4 and Interleukin-13 signaling (R-HSA-6785807 )
- IL-6-type cytokine receptor ligand interactions (R-HSA-6788467 )
- Interferon gamma signaling (R-HSA-877300 )
- Regulation of IFNG signaling (R-HSA-877312 )
- Interleukin-20 family signaling (R-HSA-8854691 )
- Interleukin-15 signaling (R-HSA-8983432 )
- Interleukin-35 Signalling (R-HSA-8984722 )
- Interleukin-9 signaling (R-HSA-8985947 )
- Interleukin-2 signaling (R-HSA-9020558 )
- Interleukin-12 signaling (R-HSA-9020591 )
- Interleukin-27 signaling (R-HSA-9020956 )
- Interleukin-21 signaling (R-HSA-9020958 )
- Interferon alpha/beta signaling (R-HSA-909733 )
- Interleukin receptor SHC signaling (R-HSA-912526 )
- Regulation of IFNA/IFNB signaling (R-HSA-912694 )
- Signaling by CSF3 (G-CSF) (R-HSA-9674555 )
- Potential therapeutics for SARS (R-HSA-9679191 )
- Inactivation of CSF3 (G-CSF) signaling (R-HSA-9705462 )
- SARS-CoV-2 activates/modulates innate and adaptive immune responses (R-HSA-9705671 )
- Interleukin-6 signaling (R-HSA-1059683 )
|
|
|
|
|
|
|
